alymsys

Generic: bevacizumab-maly

Labeler: valorum biologics, llc
NDC Directory HUMAN PRESCRIPTION DRUG BLA Inactive Finished

Drug Facts

Product Profile

Brand Name alymsys
Generic Name bevacizumab-maly
Labeler valorum biologics, llc
Dosage Form INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients

bevacizumab-maly 400 mg/16mL

Manufacturer
Valorum Biologics, LLC

Identifiers & Regulatory

Product NDC 85006-1755
Product ID 85006-1755_57bed0ca-700b-448c-a429-5aafea7b4ce9
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category BLA
Application Number BLA761231
Listing Expiration 2027-12-31
Marketing Start 2022-04-15

Pharmacologic Class

Classes
vascular endothelial growth factor inhibitor [epc] vascular endothelial growth factor inhibitors [moa] vascular endothelial growth factor-directed antibody interactions [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 850061755
Hyphenated Format 85006-1755

Supplemental Identifiers

RxCUI
2599043 2599049 2599051 2599052
UPC
0385006175519 0385006175410
UNII
2S9ZZM9Q9V

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name alymsys (source: ndc)
Generic Name bevacizumab-maly (source: ndc)
Application Number BLA761231 (source: ndc)
Routes
INTRAVENOUS
source: ndc

Resolved Composition

Strengths
  • 400 mg/16mL
source: ndc
Packaging
  • 1 VIAL in 1 CARTON (85006-1755-1) / 16 mL in 1 VIAL
source: ndc

Packages (1)

85006-1755-1 1 VIAL in 1 CARTON (85006-1755-1) / 16 mL in 1 VIAL

Ingredients (1)

bevacizumab-maly (400 mg/16mL)

Linked Drug Pages (1)

ALYMSYS ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["INTRAVENOUS"], "spl_id": "57bed0ca-700b-448c-a429-5aafea7b4ce9", "openfda": {"upc": ["0385006175519", "0385006175410"], "unii": ["2S9ZZM9Q9V"], "rxcui": ["2599043", "2599049", "2599051", "2599052"], "spl_set_id": ["42b4f96e-1f70-2126-e063-6294a90a93e3"], "manufacturer_name": ["Valorum Biologics, LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL in 1 CARTON (85006-1755-1)  / 16 mL in 1 VIAL", "package_ndc": "85006-1755-1", "marketing_start_date": "20220415"}], "brand_name": "ALYMSYS", "product_id": "85006-1755_57bed0ca-700b-448c-a429-5aafea7b4ce9", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Vascular Endothelial Growth Factor Inhibitor [EPC]", "Vascular Endothelial Growth Factor Inhibitors [MoA]", "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]"], "product_ndc": "85006-1755", "generic_name": "bevacizumab-maly", "labeler_name": "Valorum Biologics, LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "ALYMSYS", "active_ingredients": [{"name": "BEVACIZUMAB-MALY", "strength": "400 mg/16mL"}], "application_number": "BLA761231", "marketing_category": "BLA", "marketing_start_date": "20220415", "listing_expiration_date": "20271231"}